LONDON Dec 6 Britain's healthcare cost watchdog
NICE has recommended that the state health service use Sanofi's
new multiple sclerosis pill Aubagio, which will be
supplied at a discount.
The National Institute for Health and Clinical Excellence
(NICE) - the body that decides if drugs should be paid for -
said on Friday its final draft guidance recommended Aubagio, or
teriflunomide, for adults with relapsing-remitting multiple
The drug's list price is 13,529 pounds ($22,100) per patient
a year but the size of the discount has not been disclosed.
On Thursday, NICE said it needed more information before
deciding if a separate Sanofi drug for the disease - the
injectable treatment Lemtrada - was worth using.